Key Takeaways
- A corner turned, but the P&L still shows the damage: Management declared it has "definitely turned the corner" after resolving regulatory and operational issues, yet Q1 revenue and EBITDA fell sharply as Swiss development projects were deferred and the Dutch entity absorbed a margin hit from raw material costs and product mix.
- India CRAMS is the clearest proof point: Revenue from India CRAMS more than doubled YoY to Rs. 82 crores after the February 2024 EDQM clearance, and the site is now EBITDA-positive at 14%. The full-year target is Rs. 325–350 crores.
- Goodwill accounting change flatters the bottom line, not the business: The board extended goodwill amortization from 15 years to 99 years, cutting the annual P&L charge from Rs. 45 crores to ~Rs. 6 crores. This helps reported PAT but does nothing for cash or operations.
- The Dutch entity is a margin drag with a Q3 fix: A renegotiated wool grease contract should lower raw material costs from Q3, but Q1 suffered from high-cost inventory and a mix shift toward lower-margin cholesterol.
- What to watch next quarter: Whether the ~Rs. 100 crores of deferred Swiss development and commercial revenue actually materializes, the pace of the French facility ramp-up, and if Q2 EBITDA margins track above the 18% needed to hit the full-year target.
The Turnaround Narrative
- Regulatory overhang cleared: The Bavla site received final EDQM certification in February 2024 after a reinspection in September 2023, ending a multi-year restriction that had gutted a site once generating ~Rs. 400 crores in revenue. Orders from existing and new customers are now building.
- French facility finally producing: The fourth manufacturing line completed OQ and PQ validation in May 2024 and started production in June, while the second line is ready and expected to generate revenue from Q2. The French entity will still post a loss this year, but a smaller one than last year.
- Swiss deferral, not destruction: About Rs. 100 crores of development and commercial revenue at Carbogen Amcis Switzerland was deferred out of Q1, not lost. Management expects all of it to be made up over the remainder of the year.
- The confidence is anchored in Switzerland and India: The Swiss entity is expected to grow beyond CHF 20 crore, and India CRAMS is on a trajectory toward Rs. 325–350 crores this year, with Q4 historically the strongest quarter.
Pascal Villemagne: "we finally tackle all the issues we are facing, and we have definitely turned the corner"
India CRAMS: The Reopened Engine
- Revenue jump post-certification: India CRAMS revenue rose from Rs. 38 crores in Q1 last year to Rs. 82 crores this year, converting into positive EBITDA at about 14%. The February 2024 EDQM clearance was the trigger.
- Full-year target implies acceleration: Management expects Rs. 325–350 crores from India CRAMS this year, which requires the quarterly run-rate to keep climbing, with Q4 as the seasonal peak.
- Asset base can support much more: The combined Bavla and Naroda sites can generate close to Rs. 1,000 crores in revenue on the existing asset base, so the current ramp is still early in the utilization curve.
- Internal collaboration adds a second lever: The Swiss and Indian sites are collaborating to direct work to Bavla, creating a pipeline beyond standalone customer acquisition.
Harshil Dalal: "So, now because the changes that have been made between the Bavla and the Naroda site, including the operational excellence that has been brought in both sites put together can do a revenue on the existing asset base of close to about Rs. 1,000 crores."
Dutch Entity: The Margin Problem
- Raw material cost spike: Wool grease, a key input, saw a price increase that management estimates shaved 20–25% or more off the entity's EBITDA margin. The supply contract has now been renegotiated, with cost relief expected from Q3 onward.
- Product mix amplified the pain: Q1 sales skewed 60% cholesterol vs. 40% vitamin D analogues, whereas historically the higher-margin vitamin D analogues were 55% of the mix. Cholesterol's asset-grade production carries lower margins, and a large volume of it hit profitability directly.
- Inventory overhang clears in Q2: Stock purchased at higher raw material prices should work through by the end of Q2, so the P&L benefit of the renegotiated contract begins in Q3. Management is also looking for additional wool grease suppliers.
- Full-year margin should at least match last year: Despite the Q1 drag, management expects the Dutch entity's full-year EBITDA margin to be at least as good as the prior year, implying a sharp recovery in the second half.
Goodwill Accounting Change
- What changed: The board reassessed the useful life of goodwill at 99 years, effective 1 April 2024, reducing the annual amortization charge from Rs. 45 crores to ~Rs. 6 crores. The remaining goodwill on the books is Rs. 590–600 crores after Rs. 750 crores was already written off over nine years.
- Why management did it: The view is that the underlying value will not be impaired in the foreseeable future, especially with the India business recovering. Goodwill will still be tested for impairment annually.
- What it does not do: The change improves reported PAT but has no cash impact and does not alter the operating economics of any entity. An analyst pushed for a full write-off to clean up the balance sheet; management argued that accounting standards and tax implications prevent it.
- How to think about returns: Management's own advice is to evaluate return ratios after stripping out goodwill and forex impacts on assets, acknowledging that the stated book value is distorted.
French Facility Ramp-Up
- Fourth line now live: Technical issues discovered after trial batches delayed the line, but OQ and PQ validation finished in May 2024 and production began in June. The second manufacturing line is ready and should start contributing revenue from Q2.
- Losses shrinking, not gone: The French entity will remain in loss for the full financial year, but the loss will be smaller than last year. Management expects a turnaround from Q3, with losses coming down substantially, and a full-year loss of about €5 million.
- Revenue builds quarter by quarter: Revenues are expected to increase progressively each quarter as the new lines ramp, though Q2 will still show a loss.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | ~10% incremental revenue over FY24 | FY25 full year |
| EBITDA margin | ~18% for the full year; remaining three quarters must run above 18% to achieve this | FY25 full year |
| Dutch raw material cost relief | Renegotiated wool grease contract reduces cost; high-cost inventory clears by Q2 end | From Q3 FY25 |
| French entity loss | Full-year loss of ~€5 million, smaller than FY24 | FY25 full year |
| India CRAMS revenue | Rs. 325–350 crores | FY25 full year |
| Long-term EBITDA margin | Return to 25–26% | Next 2 to 3 years |
| Goodwill amortization | Reduced to ~Rs. 6 crores per annum, tested for impairment annually | Effective 1 April 2024 |
Key Metrics
| Metric | Q1 FY25 |
|---|---|
| Revenue | ₹591 cr (per an analyst's math), down from ₹723 cr in Q1 FY24; average quarterly revenue ₹600–₹650 cr |
| India CRAMS revenue | ₹82 cr, +114% YoY from ₹38 cr in Q1 FY24 |
| India CRAMS EBITDA margin | ~14%, turned positive |
| Netherlands revenue | -16% YoY, largely due to lower vitamin D analogue sales |
| French entity revenue | €1.2 million, operations began June 2024 |
| French entity EBITDA impact | -€2.5 million in Q1; full-year FY25 expected at -€5 million |
| Material cost | ₹60 cr, lower due to high-margin commercial projects sold in Q1 |
| Finance cost | ₹32 cr, in line with last year |
| Exceptional item | ₹5 cr, write-off of non-usable inventory |
| Goodwill amortization | ~₹6 cr per annum, reduced from ~₹45 cr; useful life changed to 99 years effective 1 Apr 2024 |
| Net debt | CHF 16.4 cr as of 30 Jun 2024 |
| Swiss entity development vs commercial mix | 40% development, 60% commercial in Q1; historically 55–60% development |
| Dutch entity product mix | ~60% cholesterol, ~40% vitamin D analogues in Q1; historically ~55% vitamin D, ~45% cholesterol |
| FY25 revenue growth guidance | ~10% incremental revenue over FY24 |
| FY25 EBITDA margin guidance | ~18% for the full financial year |
| Swiss entity capacity utilization | ~85%, can reach 90–95% |
| Dutch entity capacity utilization | ~65–70% |
| India CRAMS revenue potential | ~₹1,000 cr on existing asset base; FY24 revenue ~₹250 cr |